Oscar Health Stock Analysis: Buy or Sell?
1 extracted signal · 0 resolved · 1 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 17 Aug 2026, 16:15 UTC
- Recorded by Tahlil Plus
- 17 Aug 2026, 17:32 UTC
AI-generated source summary
Oscar Health (OSCR) has demonstrated significant revenue growth over the past few years, increasing from approximately $1 billion in 2021 to over $15 billion in the trailing twelve months. Its operating margin has also shown remarkable improvement, recovering from negative 90% in 2021 to 4.11% in the most recent trailing twelve months. This positive trend in operating margin is encouraging for future profitability. The return on invested capital has also seen a dramatic increase, moving from negative territory to around 30%, indicating efficient use of capital. The company's forward price-to-earnings ratio is trading at 16.10, which is near the higher end of its valuation range over the previous few years. However, a fair value estimate of $49.88 per share, based on discounted cash flow, suggests the stock is currently undervalued compared to its market price of $30.78. The intrinsic value suggests a potential upside, especially given the company's growth trajectory and improving operational efficiency.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.